Research Repository

Revising the role of the androgen receptor in breast cancer

Fioretti, FM and Sita-Lumsden, A and Bevan, CL and Brooke, GN (2014) 'Revising the role of the androgen receptor in breast cancer.' Journal of Molecular Endocrinology, 52 (3). ISSN 0952-5041

Full text not available from this repository.

Abstract

Breast cancer (BC) is traditionally viewed as an oestrogen-dependent disease in which the androgen receptor (AR) is inhibitory, counteracting the oncogenic activity of oestrogen receptor α (ERα (ESR1)). Most probably as a result of this crosstalk, the AR has prognostic value in ER-positive disease, with AR positivity reported to correlate with a better prognosis. Activation of the AR pathway has been previously used as a therapeutic strategy to treat BC, but its usage declined following the introduction of the anti-oestrogen tamoxifen. More recently, it has been demonstrated that a subset of triple-negative BCs (molecular apocrine) are dependent upon androgen signalling for growth and therapies that inhibit androgen signalling, currently used for the treatment of prostate cancer, e.g. the antiandrogen bicalutamide and the CYP17 inhibitor abiraterone acetate are undergoing clinical trials to investigate their efficacy in this BC subtype. This review summarises the current knowledge of AR activity in BC. © 2014 Society for Endocrinology.

Item Type: Article
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Science and Health > Life Sciences, School of
Depositing User: Jim Jamieson
Date Deposited: 09 Feb 2015 12:24
Last Modified: 26 Aug 2019 08:15
URI: http://repository.essex.ac.uk/id/eprint/12731

Actions (login required)

View Item View Item